Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027